Get started
Author

Terrie‐Anne Cock

Observed names: Cock, Terrie-Anne, T-A Cock, T. -a. Cock, T.-A. Cock, T.‐A. Cock, Terri-Anne Cock, Terrie-Ann Cock, Terrie-Anne Cock, Terrie-ann Cock, Terrie-anne Cock
Observed institutions: Centre National de la Recherche Scientifique, Garvan Institute of Medical Research, Inserm, The University of Queensland, GlaxoSmithKline (United Kingdom), UNSW Sydney, Institut de génétique et de biologie moléculaire et cellulaire, Phénotypage et ingénierie précliniques des systèmes d’organismes modèles, Institut de Biologie Moléculaire et Cellulaire
ORCID: 0000-0002-2928-0080
Observed ORCID: 0000-0002-2928-0080
OpenAlex ID: A5055835903
Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPARγ hypomorphic mice
2003 · Hana Koutnikova, Terrie-Anne Cock, et al. · Proceedings of the National Academy of Sciences · 182
Peroxisome proliferator‐activated receptor‐γ: too much of a good thing causes harm
2004 · Terrie‐Anne Cock, Sander M Houten, et al. · EMBO Reports · 131
Enhanced bone formation in lipodystrophic PPARγhyp/hyp mice relocates haematopoiesis to the spleen
2004 · Terrie‐Anne Cock, Jonathan Back, et al. · EMBO Reports · 121
Leptin: cutting the fat off the bone
2003 · Terrie-Anne Cock, Johan Auwerx · The Lancet · 100
Cross-talk between 1,25-Dihydroxyvitamin D3 and Transforming Growth Factor-β Signaling Requires Binding of VDR and Smad3 Proteins to Their Cognate DNA Recognition Elements
2001 · Nanthakumar Subramaniam, Gary M. Leong, et al. · Journal of Biological Chemistry · 89
Pparγ2 Is a Key Driver of Longevity in the Mouse
2009 · Carmen Argmann, Radu Dobrin, et al. · PLoS Genetics · 88
PDF
Novel N-Terminal Variant of Human VDR
2001 · K. L. Sunn, T.-A. Cock, et al. · Molecular Endocrinology · 82
PDF
Sorting of tropomyosin isoforms in synchronised NIH 3T3 fibroblasts: Evidence for distinct microfilament populations
2000 · Justin M. Percival, Gethin Thomas, et al. · Cell Motility and the Cytoskeleton · 68
Peroxisome proliferator‐activated receptor γ: the more the merrier?
2005 · C. A. Argmann, T.‐A. Cock, et al. · European Journal of Clinical Investigation · 62
PPAR-γ: A Thrifty Transcription Factor
2003 · Johan Auwerx, Terrie-Ann Cock, et al. · Nuclear Receptor Signaling · 35
Gastrointestinal hormonal responses on GPR119 activation in lean and diseased rodent models of type 2 diabetes
2014 · S Patel, O J Mace, et al. · International Journal of Obesity · 23
Promoter-, cell-, and ligand-specific transactivation responses of the VDRB1 isoform
2005 · Luis M. Esteban, Colette Fong, et al. · Biochemical and Biophysical Research Communications · 20
Local blockade of tacrolimus promotes T-cell-mediated tumor regression in systemically immunosuppressed hosts
2023 · Margaret Veitch, Kimberly Beaumont, et al. · Journal for ImmunoTherapy of Cancer · 10
PDF
The effect of adding a selective FAK inhibitor AMP945 to FOLFIRINOX in a model of pancreatic cancer.
2023 · Christopher Burns, Kendelle Murphy, et al. · Journal of Clinical Oncology · 5
Phase 1b/2a of narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel in first-line patients with advanced pancreatic cancer (ACCENT trial): Interim analysis.
2024 · Chris Burns, Terrie-Anne Cock, et al. · Journal of Clinical Oncology · 3
260. BB-HB-331, a DNA-Directed RNA Interference (ddRNAi) Agent Targeting Hepatitis B Virus (HBV), Can Effectively Suppress HBV In Vitro and In Vivo
2016 · Tin Mao, Shih-Chu Kao, et al. · Molecular Therapy · 3
PDF
PPARγ fundamental role in adipogenesis
2004 · Terrie-Anne Cock, Johan Auwerx · International Congress Series · 3
Narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel as first-line treatment for patients with metastatic pancreatic cancer (ACCENT trial): Phase 2a results.
2026 · Nick Pavlakis, Sumitra Ananda, et al. · Journal of Clinical Oncology · 2
Abstract CT220: Phase 1b/2a of narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel (Abraxane) standard of care as first-line therapy in patients with advanced pancreatic cancer (ACCENT trial): interim analysis
2024 · Terrie-Anne Cock, Anthony Bishop, et al. · Cancer Research · 2
Abstract CT087: Narmafotinib (AMP945) in combination with gemcitabine and nab paclitaxel in first-line patients with advanced pancreatic cancer (ACCENT trial) a phase 2a study: Interim analysis
2025 · Terrie-Anne Cock, Sarah Kinkel, et al. · Cancer Research · 1
Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancer
2026 · Kendelle J Murphy, Cecilia R Chambers, et al. · bioRxiv (Cold Spring Harbor Laboratory)
Abstract CT304: Narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel in first-line patients with advanced pancreatic cancer (ACCENT trial) a Phase 1b 2a study-Interim analysis
2026 · Terrie-Anne Cock, Sumitra Ananda, et al. · Cancer Research
Abstract 414: QED-203, a dual TRPV6 and AR small molecule preclinical candidate for advanced prostate cancer resistant to standard of care.
2026 · Kimberley Beaumont, Rebecca Pouwer, et al. · Cancer Research
Abstract 7106: Q-2361, a treatment for skin cancer prevention in organ transplant recipients
2026 · Rebecca Pouwer, Kimberley Beaumont, et al. · Cancer Research
Abstract A022: Combination benefit of treatment with focal adhesion kinase inhibitor narmafotinib and KRAS inhibitors
2026 · Terrie-Anne Cock, Sarah Kinkel, et al. · Cancer Research
Works count: 39
Citation count: 1,030
H-index: 12
I10-index: 13
Year
Topic
Type